Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by inforcashon Dec 13, 2007 9:44am

121 Views

Post# 14013298

RE: RE: Reimbursement

I agree with Everswan. We need to unlock the true potential of this drug before we get a buyer willing to pay 40% above the market price. Market doesn't see the full potential of this in the current SP, so instead of a buyer offering $14-15 today, why not wait a couple years---when at least 1 indication is commercialized, off label is builidng, and second indication is in the works---so we can unlock the $30+ SP, and a $40-50 buy out. Am I dreaming? don't think so.

IFC

Bullboard Posts

First Helium advances winter drilling program with Leduc Anomaly test well